Results 11 to 20 of about 21,287 (236)

Characterizing the ADPKD-IFT140 Phenotypic Signature With Deep Learning and Advanced Imaging Biomarkers

open access: yesKidney International Reports
Introduction: ADPKD-IFT140 is the third most common disease-causing variant in autosomal dominant polycystic kidney disease (ADPKD) after ADPKD-PKD1 and ADPKD-PKD2.
Abdul Hamid Borghol   +2 more
exaly   +4 more sources

Clinical practice guideline monitoring children and young people with, or at risk of developing autosomal dominant polycystic kidney disease (ADPKD) [PDF]

open access: yesBMC Nephrology, 2019
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is thought to affect about 1 in 1000 people in the UK. ADPKD causes a progressive decline in kidney function, with kidney failure tending to occur in middle age.
Jan Dudley   +11 more
doaj   +5 more sources

MR Brain Screening in ADPKD Patients [PDF]

open access: yesClinical Neuroradiology, 2021
Background Adult polycystic kidney disease (ADPKD) still represents a major cause of renal failure and intracranial aneurisms (IA) have a higher prevalence in ADPKD than in the general population.
I. Capelli   +16 more
semanticscholar   +2 more sources

Cardiovascular Manifestations and Management in ADPKD

open access: yesKidney International Reports, 2023
Cardiovascular disease (CVD) is the major cause of mortality in autosomal dominant polycystic kidney disease (ADPKD) and contributes to significant burden of disease.
P. Sagar, G. Rangan
semanticscholar   +3 more sources

Patient Perspectives on ADPKD [PDF]

open access: yesAdvances in Kidney Disease and Health, 2023
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease. It has been associated with a significant physical and psychological burden, leading to a reduced quality of life. The purpose of this literature review is to summarize the patient perspective on ADPKD based on the current published literature.
Gittus, M., Harris, T., Ong, A.C.M.
openaire   +4 more sources

Overweight and Obesity and Progression of ADPKD [PDF]

open access: yesClinical Journal of the American Society of Nephrology, 2021
Visual Abstract Background and objectives On the basis of earlier observations, we evaluated the association between overweight and obesity and rapid progression of autosomal dominant polycystic kidney disease in participants in the Tolvaptan Efficacy ...
K. Nowak   +5 more
semanticscholar   +3 more sources

Cystic Kidney Diseases That Require a Differential Diagnosis from Autosomal Dominant Polycystic Kidney Disease (ADPKD) [PDF]

open access: yesJournal of Clinical Medicine, 2022
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cystic kidney disease, with patients often having a positive family history that is characterized by a similar phenotype. However, in atypical cases, particularly those in
Akinari Sekine   +30 more
semanticscholar   +2 more sources

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

open access: yesDrug, Healthcare and Patient Safety, 2022
Rupesh Raina,1– 3 Ahmad Houry,1,3 Pratik Rath,1 Guneive Mangat,1 Davinder Pandher,1,4 Muhammad Islam,3 Ala’a Grace Khattab,3 Joseph K Kalout,1 Sumedha Bagga5 1Akron Nephrology Associates/Cleveland Clinic Akron General Medical Center, Akron, OH, USA ...
Raina R   +8 more
doaj   +2 more sources

Acute Kidney Injury in ADPKD Patients with Pneumonia [PDF]

open access: yesInternational Journal of Nephrology, 2011
Background. In animal models, polycystic kidneys are susceptible to acute kidney injury (AKI). We examined the occurrence of AKI in a cohort of autosomal dominant polycystic kidney disease (ADPKD) and non-ADPKD patients with acute pneumonia. Design.
Carlos Franco Palacios   +8 more
doaj   +2 more sources

Dietary Care for ADPKD Patients: Current Status and Future Directions [PDF]

open access: yesNutrients, 2019
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic nephropathy, and tolvaptan is the only therapy available. However, tolvaptan slows but does not stop disease progression, is marred by polyuria, and most patients worldwide ...
Sol Carriazo   +6 more
semanticscholar   +2 more sources

Home - About - Disclaimer - Privacy